This report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally. The stakeholders of this report include pharmaceutical companies and intermediaries engaged in the new drug discovery, pipeline development of various breast cancer therapeutics as well as new entrants planning to enter this market.

1. Global Breast Cancer Therapeutics Market to Log 8.3%
CAGR 2015-2023 Led by North America
Transparency Market Research has recently published a research report that presents a thorough
understanding of the trends and dynamics driving the global breast cancer therapeutics market.
The research report, titled “Breast Cancer Therapeutics Market - Global Industry Analysis, Size,
Share, Growth, Trends, and Forecast 2015 - 2023,” uses SWOT analysis to identify the strengths,
weaknesses, opportunities, and threats impacting the various market segments in the overall
market. Furthermore, the report also uses Porter’s five forces analysis to highlight the threat of
substitute products or services, the threat of new entrants, the bargaining power of customers, the
bargaining power of suppliers, and the intensity of competitive rivalry. Through its detailed
researching methods, the researchers have compiled a study that details the current market
situation as well the prospects for this market.
According to the research report, the global breast cancer therapeutics market was valued at
US$7.1 bn in 2014 and is anticipated to reach US$16.2 bn by 2023, rising at a CAGR of 8.3%
from 2015 to 2023. The drugs and therapies designed and developed for treating breast cancer
are known as breast cancer therapeutics. These include biological and regular regimens.
The global breast cancer therapeutics market has been segmented on the basis of the type of drug
and geography. The types of drugs in the global breast cancer therapeutics market are HER2
inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptor.
Geographically, this market is segmented into North America, Asia Pacific, Europe, Latin
America, and the Middle East and Africa.
The research report shows that the HER2 inhibitors segment was the largest segment of the
global breast cancer therapeutics market in 2014. It was valued at US$ 4.90 bn in 2014 and is
expected to reach US$ 9.25 bn by 2023, registering a CAGR of 6.2% from 2015 to 2023. This
segment is further sub-segmented into Herceptin (Trastuzumab), Tykerb (Lapatinib), Perjeta
(Pertuzumab), and Kadcyla (Ado-trastuzumab emtansine). The HER2 inhibitors segment is
expected to propel the overall breast cancer therapeutics market as HER2 receptor type cancer
can be easily diagnosed due to increasing advancements in targeted therapies and companion
testing.
In terms of geography, North America held a dominant share in the global breast cancer
therapeutics market in 2014. This dominance was attributable to the supportive insurance

2. schemes that cover expensive treatments for cancer patients. Analysts predict that the cancer
market in Asia Pacific is also expected to grow due to high incidence of the deadly disease,
growing awareness about breast cancer, and initiatives taken by government bodies in Asia
Pacific to tackle breast cancer.
Some of the important players in the global breast cancer therapeutics market are
GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Pfizer, Inc., F. Hoffmann-La
Roche Ltd., Eisai Co., Ltd., Novartis International AG, Puma Biotechnology, Teva
Pharmaceutical Industries Ltd., and Sanofi S.A. The research report indicates the state of the
competitive landscape of the global breast cancer therapeutics market and explains the regulatory
framework governing it. Additionally, the research report also provides a fair understanding of
the research and development activities, product portfolio, investment outlook, business and
marketing strategies, and financial overview of these top players in the coming few years.
Browse Full Research Report on Breast Cancer Therapeutics Market:
http://www.transparencymarketresearch.com/breast-cancer-therapeutics-pipeline-analysis-
market.html
The global breast cancer therapeutics market has been segmented as follows:
Global Breast Cancer Therapeutics Market, by Drug Class
•Global HER2 Inhibitors Market
oHerceptin (Trastuzumab)
oTykerb (Lapatinib)
oPerjeta (Pertuzumab)
oKadcyla (Ado-trastuzumab emtansine)
•Global Mitotic Inhibitors Market
oHalaven (Eribulin)
oTaxotere (Docetaxel)
oIxempra (Ixabepilone)
•Global Anti-metabolites Market
oGemzar (Gemcitabine)
•Global Aromatase Inhibitors Market
oFemara (Leterozole)
oAromasin (Exemestane)
oArimidex (Anastrozole)
oIbrance (Palbociclib)
oAfinitor (Everolimus)
•Global Hormone Receptor Market
oZoladex

3. oFaslodex
oFareston
Global Breast Cancer Therapeutics Market, by Geography
•North America
oU.S.
oCanada
•Europe
oGermany
oU.K.
•Asia Pacific
oJapan
oSouth Korea
oRest of Asia Pacific
•Latin America
oBrazil
oRest of Latin America
•Middle East & Africa (MEA)
Browse Full Press Release on Urgent Care Centers Market:
About Us
Transparency Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight for thousands of decision
makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that
it always reflects the latest trends and information. With extensive research and analysis
Press Release

4. capabilities, Transparency Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com